Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing

Journal of Surgical Research

Volumn 182, Issue 1, 2013, Pages 85-93

  Kleiman, David A ^a   Buitrago, Daniel ^a   Crowley, Michael J ^a   Beninato, Toni ^a   Veach, Alexander J ^b   Zanzonico, Pat B ^b   Jin, Moonsoo ^c   Fahey III, Thomas J ^a   Zarnegar, Rasa ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c School of Operations Research and Industrial Engineering   (United States)

Author keywords

BRAF (V600E) mutation; Papillary thyroid cancer; Radioactive iodine; Radioactive iodine resistance; Sodium iodine symporter; Thyroid stimulating hormone

Indexed keywords

B RAF KINASE; IODINE 131; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; THYROTROPIN; THYROTROPIN RECEPTOR;

ADULT; ALGORITHM; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; CELL LINE, TUMOR; GENE SILENCING; HUMANS; IODINE; IODINE RADIOISOTOPES; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, THYROTROPIN; RNA, SMALL INTERFERING; SYMPORTERS; THYROID NEOPLASMS; THYROTROPIN; TRANSFECTION;

EID: 84876667088     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2012.08.053     Document Type: Article

References (40)

1. C. Durante, N. Haddy, and E. Baudin Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 91 2006 2892
2. A. Antonelli, P. Fallahi, and S.M. Ferrari Dedifferentiated thyroid cancer: a therapeutic challenge Biomed Pharmacother 62 2008 559
3. R. Zarnegar, L. Brunaud, and H. Kanauchi Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor Surgery 132 2002 984 discussion 990
4. G. Riesco-Eizaguirre, and P. Santisteban A perspective view of sodium iodide symporter research and its clinical implications Eur J Endocrinol 155 2006 495
5. M. Nilsson Iodide handling by the thyroid epithelial cell Exp Clin Endocrinol Diabetes 109 2001 13
6. G. Dai, O. Levy, and N. Carrasco Cloning and characterization of the thyroid iodide transporter Nature 379 1996 458
7. T. Saito, T. Endo, and A. Kawaguchi Increased expression of the Na+/I-symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue J Clin Endocrinol Metab 82 1997 3331
8. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949
9. J.H. Lee, E.S. Lee, and Y.S. Kim Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis Cancer 110 2007 38
10. C. Michaloglou, L.C. Vredeveld, W.J. Mooi, and D.S. Peeper BRAF(E600) in benign and malignant human tumours Oncogene 27 2008 877
11. T.H. Kim, Y.J. Park, and J.A. Lim The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis Cancer 118 7 2012 Apr 1 1764
12. G. Riesco-Eizaguirre, I. Rodriguez, and A. De la Vieja The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer Cancer Res 69 2009 8317
13. J.C. Ricarte-Filho, M. Ryder, and D.A. Chitale Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Res 69 2009 4885
14. C. Durante, E. Puxeddu, and E. Ferretti BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism J Clin Endocrinol Metab 92 2007 2840
15. C. Espadinha, J.R. Santos, L.G. Sobrinho, and M.J. Bugalho Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency Clin Endocrinol (Oxf) 70 2009 629
16. G. Oler, and J.M. Cerutti High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes Cancer 115 2009 972
17. C. Romei, R. Ciampi, and P. Faviana BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer Endocr Relat Cancer 15 2008 511
18. D. Chakravarty, E. Santos, and M. Ryder Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation J Clin Invest 121 2011 4700
19. C. Nucera, M.A. Nehs, and S.S. Nagarkatti Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer Oncologist 16 2011 296
20. F. Pacini, P.W. Ladenson, and M. Schlumberger Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study J Clin Endocrinol Metab 91 2006 926
21. T. Pilli, E. Brianzoni, and F. Capoccetti A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer J Clin Endocrinol Metab 92 2007 3542
22. D.S. Cooper, G.M. Doherty, and B.R. Haugen Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167
23. C. Ma, J. Xie, and W. Liu Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer Cochrane Database Syst Rev 2010 CD008302
24. C.J. O'Neill, J. Oucharek, D. Learoyd, and S.B. Sidhu Standard and emerging therapies for metastatic differentiated thyroid cancer Oncologist 15 2010 146
25. R.E. Schweppe, J.P. Klopper, and C. Korch Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification J Clin Endocrinol Metab 93 2008 4331
26. C.S. Mitsiades, J. Negri, and C. McMullan Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol Cancer Ther 6 2007 1070
27. N. Arora, T. Scognamiglio, and C.C. Lubitz Identification of borderline thyroid tumors by gene expression array analysis Cancer 115 2009 5421
28. D. Haddad, N.G. Chen, and Q. Zhang Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus J Transl Med 9 2011 36
29. O. Levy, G. Dai, and C. Riedel Characterization of the thyroid Na+/I-symporter with an anti-COOH terminus antibody Proc Natl Acad Sci U S A 94 1997 5568
30. E.T. Kimura, M.N. Nikiforova, and Z. Zhu High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer res 63 2003 1454
31. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev 28 2007 742
32. L. Jin, T.J. Sebo, and N. Nakamura BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid Diagn Mol Pathol 15 2006 136
33. J. Kim, A.E. Giuliano, and R.R. Turner Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma Ann Surg 244 2006 799
34. K.H. Kim, D.W. Kang, and S.H. Kim Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population Yonsei Med J 45 2004 818
35. S. Yoon, and R. Seger The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions Growth factors 24 2006 21
36. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291
37. G. Galabova-Kovacs, D. Matzen, and D. Piazzolla Essential role of B-Raf in ERK activation during extraembryonic development Proc Natl Acad Sci U S A 103 2006 1325
38. C.A. Pritchard, L. Hayes, and L. Wojnowski B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts Mol Cell Biol 24 2004 5937
39. G. Galabova-Kovacs, A. Kolbus, and D. Matzen ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts Cell cycle 5 2006 1514
40. D. Liu, S. Hu, and P. Hou Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant Clin Cancer Res 13 2007 1341